



Rutgers Cancer Institute Auto/Allo, Bispecific CAR T Tumor Board

This activity is provided by Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School,
Department of Radiology and Department of Pathology

Interesting Cases of the Week

Rutgers Cancer Institute, East Tower, 9th Floor, Room 916

Zoom Link: <https://rutgers.zoom.us/j/94889982860?pwd=UTVsV29QMnZMld0a0xUZDRWS1podz09&from=addon>

Thursday, April 9, 2026 - 1:00-2:00PM

Presenters: Ogechukwu Egini, MD, Dale Schaar, MD, PhD,
Mansi Shah, MD, Nicole McEntee, MSN, OCN, BMTCN, Emma Rabinovich, MD

Learning Objectives

At the conclusion of this activity, participants should be better able to:

1. Demonstrate an improved understanding of cellular therapies for blood cancers.
2. Describe recent advances in cellular therapies and their clinical implications.
3. Evaluate and select appropriate cellular therapies for specific patient cases, comparing them with alternative treatment options.
4. Analyze the safety profiles of cellular therapies in comparison to other treatment modalities.
5. Identify and apply alternative strategies to enhance patient outcomes and quality of life.

Target Audience

This activity is designed for medical oncologists, pharmacists, surgical oncologists, general surgeons, radiation oncologists, radiologists, hematologists, pathologists, physician assistants, nurses, and nurse practitioners.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 ANCC contact hour

Pharmacists: This knowledge-based activity qualifies for 1 contact hour of continuing pharmacy education credit.

Disclosure Declarations

Speakers, Planning Committee and Content Reviewers: Ogechukwu Egini, MD; Emma Rabinovich, MD (Activity Director); and Dale Schaar, MD, PhD have no relevant financial relationships with ineligible companies to disclose.

Speakers and Planners: The following individuals have relevant financial relationships with ineligible companies: Nicole McEntee, MSN: Consultant: Bristol Myers Squibb, Merck; Mansi Shah, MD: Consultant: Bristol Myers Squibb, Johnson & Johnson, Pfizer, Regeneron Pharmaceuticals; Grant/Research Support: AbbVie, Bristol Myers Squibb, Janssen Pharmaceuticals, Regeneron Pharmaceuticals; Paid Speaker: Johnson & Johnson. All of the relevant financial relationships listed have been mitigated.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.



Planner and Content Reviewer: Michael P. Kane, RPh: have no relevant financial relationships with ineligible companies to disclose.

Planners: Rutgers Health CE Staff. Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.